---
title: "Paxlovid (nirmatrelvir; ritonavir), all indications: Clinical trials questions"
description: "Clinical trials questions on Paxlovid (nirmatrelvir; ritonavir) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Resistance. Questions: Does resistance to Paxlovid develop during treatment? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/paxlovid/clinical-trials"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir), all indications: Clinical trials questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)  
Indication pages: [COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)

## Resistance

<a id="paxlovid-treatment-emergent-resistance"></a>

### Does resistance to Paxlovid develop during treatment?

> “Treatment-emergent substitutions were evaluated among subjects in clinical trials EPIC-HR/SR with sequence data available at both baseline and post-baseline visits (n=907 PAXLOVID-treated subjects, n=946 placebo-treated subjects). SARS-CoV-2 Mpro amino acid changes were classified as PAXLOVID treatment-emergent substitutions if they occurred at the same amino acid position in 3 or more PAXLOVID-treated subjects and were ≥2.5-fold more common in PAXLOVID-treated subjects than placebo-treated subjects. The following PAXLOVID treatment-emergent Mpro substitutions were observed: T98I/R/del(n=4), E166V (n=3), and W207L/R/del (n=4). In biochemical assays, the T98I and W207L/R substitutions did not affect nirmatrelvir activity (Ki value fold changes were 0.3 and 0.7/0.3, respectively), whereas the E166V substitution (which occurs at a Mpro-nirmatrelvir contact residue) reduced nirmatrelvir activity 187-7,700-fold. Within the Mpro cleavage sites, the following PAXLOVID treatment-emergent substitutions were observed: A5328S/V(n=7) and S6799A/P/Y (n=4). These cleavage site substitutions were not associated with the co-occurrence of any specific Mpro substitutions. In a cell culture replicon assay, the A5328S/V and S6799A substitutions did not affect nirmatrelvir activity (EC50 value fold changes were 0.3/0.2 and 0.7, respectively).
>
> None of the treatment-emergent substitutions listed above in Mpro or Mpro cleavage sites occurred in PAXLOVID-treated subjects who experienced hospitalization. Thus, the clinical significance of these substitutions is unknown.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Treatment%2Demergent%20substitutions%20were%20evaluated%20among,of%20these%20substitutions%20is%20unknown.)

> “In EPIC-HR, of 59 PAXLOVID-treated subjects identified with post-treatment viral RNA rebound and with available viral sequence data, treatment-emergent substitutions in Mpro potentially reducing nirmatrelvir activity were detected in 2 (3%) subjects, including E166V in 1 subject and T304I in 1 subject. Both subjects had viral RNA shedding levels <LLOQ by Day 14.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=In%20EPIC%2DHR%2C%20of%2059%20PAXLOVID%2Dtreated,levels%20%3CLLOQ%20by%20Day%2014.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): All indications](https://www.evicenter.com/medical-information/paxlovid)
- [Indication](https://www.evicenter.com/medical-information/paxlovid/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/paxlovid/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/paxlovid/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/paxlovid/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid/access-and-coverage)
